Long-term clinical outcomes from the smart start trial: rituximab, lenalidomide and ibrutinib in patients with newly diagnosed large B-cell lymphoma.
Saved in:
| Title: | Long-term clinical outcomes from the smart start trial: rituximab, lenalidomide and ibrutinib in patients with newly diagnosed large B-cell lymphoma. |
|---|---|
| Authors: | Chohan KL; Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Saul EE; Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Davis RE; Department of Lymphoma & Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Hagemeister F; Department of Lymphoma & Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Steiner R; Department of Lymphoma & Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Fayad L; Department of Lymphoma & Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Ahmed S; Department of Lymphoma & Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Rodriguez A; Department of Lymphoma & Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Iyer SP; Department of Lymphoma & Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Nair R; Department of Lymphoma & Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Vega F; Department of Hematopathology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Chihara D; Department of Lymphoma & Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Strati P; Department of Lymphoma & Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Jain P; Department of Lymphoma & Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Malpica Castillo L; Department of Lymphoma & Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Nze C; Department of Lymphoma & Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Furqan F; Department of Lymphoma & Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Chauhan A; Department of Lymphoma & Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Hamilton MP; Department of Lymphoma & Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Henderson J; Department of Lymphoma & Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Lionel AC; Department of Lymphoma & Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Flowers CR; Department of Lymphoma & Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Neelapu S; Department of Lymphoma & Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Green MR; Department of Lymphoma & Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Westin J; Department of Lymphoma & Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX, USA. jwestin@mdanderson.org. |
| Source: | Blood cancer journal [Blood Cancer J] 2026 Jul 02; Vol. 16 (1). Date of Electronic Publication: 2026 Jul 02. |
| Publication Type: | Letter |
| Journal Info: | Publisher: Nature Pub. Group Country of Publication: United States NLM ID: 101568469 Publication Model: Electronic Cited Medium: Internet ISSN: 2044-5385 (Electronic) Linking ISSN: 20445385 NLM ISO Abbreviation: Blood Cancer J Subsets: MEDLINE; In Process |
| Database: | MEDLINE Ultimate |
|
Full text is not displayed to guests.
Login for full access.
|
|
| ISSN: | 2044-5385 |
|---|---|
| DOI: | 10.1038/s41408-026-01524-9 |
